Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Banerjee says a patient from her phase 1 study stayed on avutometinib plus defactinib for about five years, showing durable efficacy and tolerability. She stresses it is active treatment rather than maintenance and would continue it in her practice until progression unless side effects limit tolerability.

Related Insights

While initial response rates are similar between the Avutometinib/Defactinib doublet and single-agent Trametinib, the doublet provides double the progression-free survival (PFS). Its remarkable duration of response (over 30 months) indicates superior long-term disease control.

A patient on trastuzumab deruxtecan (TDXD) for seven years with no evidence of disease and no toxicity chose to continue the drug, declining to switch to a standard maintenance regimen. This illustrates a real-world challenge where patient preference and excellent outcomes can override the clinical logic of treatment de-escalation.

With pirtobrutinib, time to next treatment often exceeds progression-free survival. This discrepancy exists because disease progression is frequently slow and asymptomatic, meaning clinicians do not need to switch therapies immediately upon seeing radiographic changes, allowing for longer treatment duration.

As various maintenance therapies (immunotherapy, ADCs) are integrated into endometrial cancer treatment, the next major clinical question is defining how long these agents need to be continued to maximize benefit while minimizing long-term toxicity and patient burden.

The LITESPARK 011 trial showed the Lenvatinib/Belzutifan combination doubled the duration of response compared to Cabozantinib. This durability, with some patients in remission for over three years, is considered a more significant clinical advance than the modest increase in overall response rate, representing a key differentiator for the regimen.

Tyrosine kinase inhibitors (TKIs) have dramatically increased median overall survival for GIST patients from nine months to over seven years. Some patients have now been on therapy for over 20 years. This longevity transforms GIST into a chronic condition, making long-term side effect management and quality of life critical for maintaining treatment adherence and efficacy.

The doublet's unique dosing schedule (twice-weekly pills for three weeks, then one week off) is crucial for its long-term success. This "recovery week" per cycle is thought to reduce cumulative toxicity, allowing patients to stay on this highly effective therapy for extended periods.

While patients often request drug vacations due to cost and chronic reminders of cancer, stopping therapy prematurely risks rapid relapse. Clinicians emphasize that attempting planned discontinuation requires at least two years on drug and an established clinical response, although prospective randomized validation remains ongoing.

An expert expresses a strong preference for time-limited CLL therapies over continuous maintenance treatments. The rationale is that getting patients into a deep remission and then off treatment entirely leads to a better overall experience and quality of life, even if they eventually relapse.

The new standard for first-line HER2+ breast cancer, TDXD-pertuzumab, has superior efficacy. However, experts are questioning if treating until disease progression is optimal for all, suggesting a switch to maintenance therapy could better balance side effects and quality of life. The ideal duration remains an open question.

Avutometinib-defactinib is treatment, not maintenance, until progression | RiffOn